We’ve been waiting patiently for results of a Norwegian human, clinical trial studying NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews). The Niagen folks shared developments on their earnings call last night:

Dr. Andrew Shao:

”Regarding Parkinson’s disease, as Rob mentioned in his remarks, the NOPARK study did not achieve its primary endpoint.

We have been in close contact with the investigators from Haukeland University Hospital in Bergen, Norway, led by Dr. Charalampos Tzoulis. We, together with Dr. Tzoulis, believe when it comes to Parkinson’s, the benefit of NAD augmentation with NR may be best applied prior to disease and treatment onset; in other words, as a preventative. We plan to collaborate with Dr. Tzoulis to examine the preventive effects of NR and its mechanism related to Parkinson’s through a new partnership we will announce soon. In the meantime, Dr. Tzoulis is continuing his research on the therapeutic effects of NR in Parkinson’s and other neurodegenerative conditions, including ALS and MS.

CEO Rob Fried:

We are waiting for the final manuscript and discussion with Tzoulis. He is very bullish on this idea that it is a preventative before the standard of care of L-DOPA and the diagnosis of Parkinson’s, and he has an amount of data to support that idea. At this point, we are waiting to hear from him on that. Andrew, is there anything more you want to contribute to that?

Andrew Shao:

Just like you said, Rob, the manuscript will be submitted for publication shortly here, so we cannot divulge any of those details. But we will be collaborating with Dr. Tzoulis, as I mentioned in my remarks, with a focus more toward looking at prevention.

Related:

FOLLOW us on Twitter @RaisingNAD